The Effect of Metabolic Syndrome Status on Lung Function and Patient-reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
LAMA
chronic obstructive pulmonary disease
copd
eFlow
glycopyrrolate
metabolic syndrome
nebulized long-acting muscarinic antagonist
Journal
Chronic obstructive pulmonary diseases (Miami, Fla.)
ISSN: 2372-952X
Titre abrégé: Chronic Obstr Pulm Dis
Pays: United States
ID NLM: 101635411
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
22
8
2020
medline:
22
8
2020
entrez:
22
8
2020
Statut:
ppublish
Résumé
Concurrent chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MetS) represent an important clinical phenotype with overlapping symptomology. The effect of MetS in COPD patients was assessed following treatment with nebulized glycopyrrolate (GLY; administered via eFlow® Closed System Nebulizer). Posthoc analyses were performed on pooled lung function, patient-reported outcome (PRO) and safety data by MetS status from patients treated with placebo, GLY 25 and 50 mcg twice daily in two 12-week studies (GOLDEN 3 and 4; N=1293). Patients with MetS were characterized as having ≥ 3 of hypertension, hyperlipidemia, diabetes, body mass index (BMI) > 30 kg/m A total of25% of patients met MetS criteria.At baseline, the MetS subgroup had higher BMIs, more ex-smokers, greater incidences of cardiovascular risk factors, and MetS-specific risk factors were 2-14 times higher than non-MetS. At 12 weeks, GLY produced significant, clinically important improvements (MetS: 0.121 L; non-MetS: 0.083 L) in trough forced expiratory volume in 1 second. In the non-MetS group, significant improvements occurred in the St George's Respiratory Questionnaire (MetS: -2.28, GLY was well-tolerated and significantly improved lung function regardless of MetS status, while significant PRO improvements occurred in non-MetS patients. These results highlight the importance of comorbidities on bronchodilator responses and patient symptoms in COPD patients.
Sections du résumé
BACKGROUND
BACKGROUND
Concurrent chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MetS) represent an important clinical phenotype with overlapping symptomology. The effect of MetS in COPD patients was assessed following treatment with nebulized glycopyrrolate (GLY; administered via eFlow® Closed System Nebulizer).
METHODS
METHODS
Posthoc analyses were performed on pooled lung function, patient-reported outcome (PRO) and safety data by MetS status from patients treated with placebo, GLY 25 and 50 mcg twice daily in two 12-week studies (GOLDEN 3 and 4; N=1293). Patients with MetS were characterized as having ≥ 3 of hypertension, hyperlipidemia, diabetes, body mass index (BMI) > 30 kg/m
RESULTS
RESULTS
A total of25% of patients met MetS criteria.At baseline, the MetS subgroup had higher BMIs, more ex-smokers, greater incidences of cardiovascular risk factors, and MetS-specific risk factors were 2-14 times higher than non-MetS. At 12 weeks, GLY produced significant, clinically important improvements (MetS: 0.121 L; non-MetS: 0.083 L) in trough forced expiratory volume in 1 second. In the non-MetS group, significant improvements occurred in the St George's Respiratory Questionnaire (MetS: -2.28,
CONCLUSION
CONCLUSIONS
GLY was well-tolerated and significantly improved lung function regardless of MetS status, while significant PRO improvements occurred in non-MetS patients. These results highlight the importance of comorbidities on bronchodilator responses and patient symptoms in COPD patients.
Identifiants
pubmed: 32822528
doi: 10.15326/jcopdf.7.4.2020.0145
pmc: PMC7883902
doi:
Types de publication
Journal Article
Langues
eng
Pagination
315-326Subventions
Organisme : Sunovion Pharmaceuticals, Inc.
Pays : United States
Informations de copyright
JCOPDF © 2020.
Déclaration de conflit d'intérêts
Dr. Brian Carlin has served on speakers’ bureaus for Sunovion Pharmaceuticals Inc., and GlaxoSmithKline and is an advisory board member for Sunovion Pharmaceuticals Inc., GlaxoSmithKline, and Theravance. Dr. Gary T. Ferguson reports grants, personal fees, and non-financial support from Sunovion Pharmaceuticals Inc., during the conduct of the study; Dr Ferguson has also received grants, personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, Novartis, Pearl Therapeutics, Sunovion, Theravance, and GlaxoSmithKline; grants and personal fees from Verona and Sanofi; grants from Altavant; and personal fees from Mylan, Innoviva and Circassia. Dr. Ayca Ozol-Godfrey, Dr. Thomas Goodin, and Dr. Shahin Sanjar are employees of Sunovion Pharmaceuticals, Inc.
Références
Eur Respir Rev. 2013 Dec;22(130):454-75
pubmed: 24293462
Eur Respir J. 2008 Oct;32(4):962-9
pubmed: 18579551
J Cardiopulm Rehabil. 2005 Jul-Aug;25(4):226-32; discussion 233-4
pubmed: 16056071
Am J Respir Crit Care Med. 2012 Jul 15;186(2):155-61
pubmed: 22561964
Eur Respir J. 2010 Feb;35(2):317-23
pubmed: 19574332
Asian Nurs Res (Korean Soc Nurs Sci). 2019 May;13(2):137-146
pubmed: 30910730
Pharmacol Ther. 2019 Jun;198:160-188
pubmed: 30822464
Clin Cardiol. 2018 Jul;41(7):959-965
pubmed: 29797803
PLoS One. 2017 Oct 24;12(10):e0186708
pubmed: 29065130
Chest. 2009 Oct;136(4):1039-1046
pubmed: 19542257
Respir Res. 2014 Oct 07;15:124
pubmed: 25287629
COPD. 2011 Dec;8(6):414-20
pubmed: 22149401
PLoS One. 2014 Jun 20;9(6):e98013
pubmed: 24950070
COPD. 2005 Mar;2(1):75-9
pubmed: 17136966
JAMA. 2015 May 19;313(19):1973-4
pubmed: 25988468
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Respir Med. 2017 Nov;132:238-250
pubmed: 28838685
COPD. 2016 Jun;13(3):399-406
pubmed: 26914392
BMC Public Health. 2017 Jan 21;17(1):101
pubmed: 28109251
West J Nurs Res. 2014 May;36(5):620-42
pubmed: 24292806